Nevro, Globus

Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio
Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% premium over its 90-day volume-weighted average price and a 17% premium over its closing price on Feb.
Globus Medical to acquire Nevro for $250M
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Globus to buy Nevro for $250M
Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale and orthopedic relationships.
Globus Medical to buy California life sciences firm for $250M
Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain for $250 million in cash. Audubon-based Globus (NYSE: GMED) will pay $5.85 per share for Nevro Corp. (NYSE: NVRO), representing a 17% premium to the company's closing stocking price on Wednesday.
Globus Medical to buy Nevro in $250M all-cash deal
Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's (NVRO) stock for $5.
Globus Medical to Acquire Nevro Corp. in Strategic $250 Million Deal
Globus Medical (NYSE: GMED) has announced a definitive agreement to acquire all shares of Nevro Corp. (NYSE: NVRO) in an all-cash transaction worth approximately
Zacks.com on MSN9h
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?
Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Hosted on MSN1h
Nevro (NVRO) Upgraded to Buy: What Does It Mean for the Stock?
Nevro (NVRO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...
TMCnet1d
NVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Nevro Corp. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is fair to Nevro shareholders.
Nasdaq15d
Here's Why you Should Add Nevro Stock to Your Portfolio Now
Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 ...
Nevro price target raised to $5.85 from $4 at Canaccord
Canaccord raised the firm’s price target on Nevro (NVRO) to $5.85 from $4 and keeps a Hold rating on the shares. The firm noted Globus Medical ...